FIELD: biotechnology.
SUBSTANCE: following is proposed: a designed peptide including the sequence SEQ ID No.1, forming a homodimer capable of effectively binding to DED1 domain of c-FLIP protein.
EFFECT: designed peptide promotes the induction of apoptosis and can be used in the development of effective cancer treatment methods.
1 cl, 3 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTIFUNCTIONAL HYBRID RECOMBINANT PROTEIN MEDICINAL PRODUCTS FOR THE TREATMENT OF TUMOR DISEASES | 2022 |
|
RU2801367C1 |
| METHOD OF SUPPRESSING GROWTH OF TUMOURS WITH GENETICALLY MODIFIED VERSION OF TRAIL CYTOKINE | 2019 |
|
RU2727059C1 |
| APOPTOTIC Apo2L/TRAIL SENSITIVITY BY TESTING GalNac-T14 EXPRESSION IN CELLS/TISSUES | 2006 |
|
RU2416097C2 |
| COMBINATION OF ANTIBODY HAVING SELECTIVITY IN RELATES TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR AND OTHER THERAPEUTIC AGENTS | 2002 |
|
RU2313368C2 |
| METHOD OF PRODUCING HUMAN RECOMBINANT ANTI-TUMOUR PROTEIN DR5-B | 2018 |
|
RU2687435C1 |
| ANTIBODY SELECTIVE TO RECEPTOR APOPTOSIS-INDUCING LIGAND AND ASSOCIATED WITH TUMOR NECROSIS FACTOR AND ITS USING | 2002 |
|
RU2313537C2 |
| APOPTOSIS DETECTION TECHNIQUES AND REAGENTS | 2007 |
|
RU2450273C2 |
| ANTIBODY SELECTIVE TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR, AND USES THEREOF | 2001 |
|
RU2298013C2 |
| ANALYSES AND METHODS OF BIOMARKER APPLICATION | 2006 |
|
RU2409817C2 |
| METHOD FOR TUMOUR CELL DEATH INDUCTION | 2015 |
|
RU2620165C2 |
